iPS Cells & Regenerative Medicine– category –
-
iPS Cells & Regenerative Medicine Weekly Report August 16, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 16, 2026 (PDF) — Download Weekly Report August 16, 2026 (PDF) — DownloadDownload 🎙 Podcast August 16, ... -
PTC Therapeutics and Eli Lilly to Acquire Sangamo Assets for Up to $264M in Bankruptcy Auction, Bolstering Rare Disease Pipelines
Endpoints News USA Overview PTC Therapeutics and Eli Lilly are set to acquire parts of the bankrupt gene editing biotech Sangamo for up to $264 million following an auction. PTC Therapeutics will acquire Sangamo's Fabry disease candidate... -
Precision and Pace: Liv Hospital Details Step-by-Step Innovations in CAR-T Cell Manufacturing
Liv Hospital Turkey Overview Liv Hospital has released a comprehensive, step-by-step guide to CAR-T cell manufacturing, spanning the entire process from leukapheresis to final formulation. The blueprint emphasizes stringent quality contr... -
Overcoming Raw Material Variability Challenges for Autologous Adoptive Cell Therapies: Risk-Based Control and Decentralized Manufacturing
PharmTech International Overview Raw material variability presents a significant challenge to product consistency and quality in autologous cell therapy manufacturing. A risk-based, phase-appropriate control strategy is crucial, identify... -
Merck Expands Singapore BioReliance Lab with Asia Pacific’s First Cell Line Characterization and GMP NGS Capabilities
BioPharma APAC Singapore Overview Merck is expanding its Singapore BioReliance lab to strengthen analytical and biosafety testing services in the Asia Pacific region. The expanded facility will offer the first BioReliance Cell Line Chara... -
China’s Hopstem Biotech Secures Nearly RMB 200 Million in Series C First Close to Advance iPSC Cell Therapy Pipeline Led by hNPC01
Insight, China's Pharmaceutical Industry China Overview China's Hopstem Biotech has completed the first close of nearly RMB 200 million (approximately $27.5 million USD) in Series C funding to advance its iPSC cell therapy pipeline, led ... -
XsellSmart Biopharmaceutical Completes Patient Enrollment in Phase 1 Trial for Universal Cell Therapy XS411 in Parkinson’s-Type Multiple System Atrophy
VCBeat China Overview XsellSmart Biopharmaceutical announced the completion of full participant enrollment in its Phase 1 registrational clinical trial for XS411, a universal cell therapy targeting Parkinson's-type multiple system atroph... -
Chronic Exposure to Chlorate at Regulatory Safety Limits Induces p21/p16-Mediated Neuronal Senescence and Parkinsonian Decline in iPSC-Derived Neurons
PubMed International Overview This research reports that chronic exposure to chlorate at concentrations within regulatory safety limits accelerates neuronal senescence in human iPSC-derived dopaminergic neurons, leading to Parkinsonian-l... -
Intellia Therapeutics Advances CRISPR Gene Therapy Pipeline, Including NTLA-2002 for HAE
Tracxn USA Overview Intellia Therapeutics is a public company advancing therapeutics based on CRISPR/Cas9 technology, with its lead candidate, NTLA-2002, an investigational CRISPR therapy for hereditary angioedema (HAE). The company also... -
Rapid Rise of iPSC-Based Therapies: Manufacturing Challenges and FUJIFILM Cellular Dynamics’ Automation Solutions
Contract Pharma International Overview iPSC-based therapies are rapidly advancing as a renewable, standardized source for allogeneic treatments and scalable solutions across various indications. However, manufacturing poses challenges in...
